INTRODUCTION
============

Gastric cancer is the fifth most common malignancy and is the third leading cause of cancer death worldwide; half of new cases occur in Asia, including in China ([@R1], [@R2]). The high incidence and mortality rates in China possibly result from the differences in *Helicobacter pylori* infection and behavioral risk factors, as well as genetic diversity in particular ([@R3], [@R4]). In recent decades, genome-wide association studies (GWASs) have identified several gastric cancer risk--related single-nucleotide polymorphisms (SNPs) ([@R5]--[@R11]), and most of them were confirmed to be potentially useful as high-quality biomarkers for the programs of gastric cancer susceptibility screening and prognostic evaluation ([@R12]--[@R14]).

In addition to GWAS, some risk loci for gastric cancer were also identified in hypothesis-driven studies based on biological relevance. However, because of the small sample size, most risk loci only explain a small proportion of the phenotypic variance and thus lead to publication bias ([@R13]). The currently reported risk loci only explain 1.07% of the phenotypic variance in gastric cancer ([@R13]), a value that is much lower than the 22% of phenotypic variance explained by heritability from a twin study ([@R15]). Moreover, the molecular mechanisms of risk variants and their assigned genes in gastric cancer have rarely been comprehensively investigated. Several researchers have proposed the idea of "from association to function" in the post-GWAS era to delineate the causal variants and biological mechanisms underlying disease risk, including cancer etiology and pathology ([@R16], [@R17]).

Thus, there is an urgent need to perform an in-depth analysis of gastric cancer GWAS to explore the remaining "missing heritability" and to reveal its underlying causal mechanism. In this study, we used an integrated analytical strategy to explore potential causal genetic variants and susceptibility genes for gastric cancer in a large-scale cross-ancestry population. A series of in vitro and in vivo experiments were applied to investigate the genetic and epigenetic biological impacts on gastric oncogenesis.

RESULTS
=======

Study overview
--------------

The flowchart of this study is shown in [Fig. 1A](#F1){ref-type="fig"}. First, a two-step gene-set analysis with both distribution-based sets and gene-based sets was performed for gastric cancer GWAS. Second, the fine-mapping and functional analyses were conducted to identify potential causal risk variants in candidate genes. Third, a large-scale cross-ancestry population was used to evaluate the effect of candidate genetic variants on gastric cancer risk. Last, molecular experiments were performed to interpret the biological significance of risk variants and genes.

![The procedures of gene-set analysis of gastric cancer risk.\
(**A**) Flowchart of the study design. (**B**) Global map of the distribution of genetic variants by gene types, including protein-coding genes (red), noncoding RNAs (ncRNAs) (blue), the combination (orange), and intergenic regions (green). (**C**) Application of the gastric cancer GWAS. (**D**) Distribution-based gene-set analysis, including intervals of protein-coding genes, ncRNA genes, the combination, and intergenic regions. The top panel shows the SNP numbers, and the bottom panel shows the *P* value. (**E**) Gene-based gene-set analysis. The top panel shows the SNP numbers, and the bottom panel shows the *P* value. (**F**) The linkage disequilibrium plots based on Asian populations (Han Chinese in Beijing and Japanese in Tokyo from 1000 Genomes Project; left) and functional annotation with scores from RegulomeDB and HaploReg (right) for the third novel gene set. DNase, deoxyribonuclease.](aay5525-F1){#F1}

The distribution of whole-genome and cancer risk genetic variants
-----------------------------------------------------------------

The genes present in the genome were primarily divided into two major categories: protein-coding genes and noncoding RNA (ncRNA) genes (fig. S1A and table S1). The genes were subsequently used to annotate the distributions of the genome-wide genetic variants, pan-cancer risk variants, and gastric cancer--specific risk variants ([Fig. 1B](#F1){ref-type="fig"}). The variants were mainly located at four subgroup intervals with different distribution proportions, including protein-coding genes, ncRNA genes, combined intervals of protein-coding and ncRNA genes (abbreviated as "the combination"), and intergenic regions (fig. S1 and table S2). Greater than 60% of gastric cancer risk variants were enriched in the combination compared with that in 1000 Genomes Project (24.6%; *P* = 2.07 × 10^−5^) and pan-cancer risk variants (31.2%; *P* = 5.76 × 10^−4^), suggesting the potential biological effect of the combined loci of protein-coding and ncRNA loci on gastric cancer susceptibility.

Identification of novel risk loci
---------------------------------

After imputation and quality control for the gastric cancer GWAS dataset, 499 variants with *P* \< 1.0 × 10^−4^ were included in the gene-set analysis ([Fig. 1C](#F1){ref-type="fig"} and table S3). According to the aforementioned distribution patterns, we primarily performed a distribution-based analysis, which showed the strongest association between 110 SNPs in the subgroup of the combination and gastric cancer risk (*P* = 1.14 × 10^−24^; [Fig. 1D](#F1){ref-type="fig"} and table S4). We subsequently conducted a second gene-set analysis with delicate gene annotation for 110 SNPs to clearly define the key genes with substantial effects. The gene-based sets harboring *PLCE1* and *MUC1* displayed the top two strongest associations with gastric cancer risk, consistent with the data from the original study ([@R6]) (*P* = 3.53 × 10^−10^ for the *PLCE1* set and *P* = 9.03 × 10^−7^ for the *MUC1* set; [Fig. 1E](#F1){ref-type="fig"} and table S4). In the present study, the gene set with the third strongest effect served as a candidate for further investigation (i.e., 15 SNPs in the *RP11-166B2.1*\|*TNFRSF17* set with *P* = 2.11 × 10^−6^; [Fig. 1E](#F1){ref-type="fig"} and table S4).

Functional assessment and determination of causal variants
----------------------------------------------------------

We used a fine-mapping credible set analysis to identify the potential causal variants and to further dissect their effects on driving the changes in the expression of the novel regions ([@R18]). Among the 15 candidate SNPs located in the *RP11-166B2.1*\|*TNFRSF17* set, three tagSNPs were identified with high posterior probability (0.940 for rs3850997, 1.000 for rs11570151, and 0.971 for rs446289; table S5). In addition, we performed a functional annotation analysis to nominate putative causal variants and found that three tagSNPs, which are located in evolutionarily conserved and functional elements (fig. S2A), not only presented high functional scores (6 for rs3850997, 4 for rs11570151, and 6 for rs446289; [Fig. 1F](#F1){ref-type="fig"} and table S5) but also exhibited high integrated haplotype scores (iHSs) (fig. S2B). Moreover, all three tagSNPs exerted strong pleiotropic expression quantitative trait loci (eQTL) effects on the expression of multiple genes in each tissue, of which only rs3850997 and rs446289 exerted allele-specific effects on *RP11-166B2.1* expression in stomach tissues (fig. S3).

Because the causal variants might exert consistent genetic effects across populations with less heterogeneity, we subsequently evaluated the genetic impacts of these 15 candidate SNPs in a European population. Similarly, rs3850997, but not the other SNPs, presented a significant association with gastric cancer risk \[odds ratio (OR) = 0.74, 95% confidence interval (CI) = 0.59 to 0.93, *P* = 9.26 × 10^−3^ for the G allele; [Table 1](#T1){ref-type="table"} and table S6\]. Moreover, the conditional analysis pinpointed out an independent effect of rs3850997 on gastric cancer risk after adjusting the GWAS-SNP rs2274223 genotypes (table S7) ([@R6]). Thus, rs3850997 likely drove the effect of the *RP11-166B2.1*\|*TNFRSF17* region on gastric cancer risk.

###### Association between rs3850997 and gastric cancer risk in GWAS and validation stages.

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium. The covariates of age, sex, and study design were adjusted in GWAS stage; the covariates of age and sex were adjusted in the Nanjing-1, Nanjing-2, Yixing, Nantong, and Jilin stages; and sex was adjusted in both the Nanjing-3 and European stages.

  **Stages**     **Population**   **Cases/controls**   **rs3850997 genotypes (TT/TG/GG)**   **MAF (G allele)**   ***P*~HWE~**   **OR (95% CI)\***   ***P*\***           
  -------------- ---------------- -------------------- ------------------------------------ -------------------- -------------- ------------------- ------------------- ---------------
  GWAS           Shanxi/Linxian   1625/2100            661/720/241                          706/1052/342         0.371/0.413    0.131               0.83 (0.75--0.91)   9.29 × 10^−5^
  Validation-1   Nanjing-1        1275/1436            473/612/170                          489/715/228          0.379/0.409    0.213               0.87 (0.78--0.98)   1.73 × 10^−2^
  Validation-2   Nanjing-2        1021/1203            398/424/163                          442/552/206          0.381/0.401    0.136               0.92 (0.81--1.03)   1.50 × 10^−1^
  Validation-3   Nanjing-3        550/1155             205/256/69                           400/555/175          0.372/0.400    0.458               0.88 (0.76--1.03)   1.09 × 10^−1^
  Validation-4   Yixing           940/1061             366/416/145                          339/518/164          0.381/0.414    0.147               0.87 (0.76--0.99)   3.02 × 10^−2^
  Validation-5   Nantong          471/652              167/218/65                           225/319/97           0.387/0.400    0.353               0.96 (0.80--1.14)   6.18 × 10^−1^
  Validation-6   Jilin            1096/1178            402/510/155                          405/541/199          0.384/0.410    0.428               0.89 (0.79--1.01)   6.19 × 10^−2^
  Combined^†^                     6978/8785                                                                                                         0.87 (0.84--0.92)   2.43 × 10^−8^
                 European         254/2835             29/99/103                            222/1027/1186        0.660/0.698    1.000               0.74 (0.59--0.93)   9.26 × 10^−3^
  Combined^†^                     7232/11,620                                                                                                       0.87 (0.83--0.91)   2.13 × 10^−9^

\*The additive genetic model used in the logistic regression analysis was constructed to detect the association between rs3850997 and gastric cancer risk.

†A meta-analysis was performed for the combined group with *P*~heterogeneity~ = 0.820 for Asian populations and 0.669 for all populations.

Evaluation of the genetic effect of rs3850997 on gastric cancer risk
--------------------------------------------------------------------

SNP rs3850997 was subsequently genotyped in six independent case-control populations. As shown in [Table 1](#T1){ref-type="table"}, rs3850997 displayed the same directional effect of the G allele on gastric cancer risk, with ORs ranging from 0.87 to 0.96, although the *P* value for the association intensity ranged from 0.017 to 0.618. When combined, the effect of rs3850997 reached genome-wide significance for an association with gastric cancer risk in a Chinese population (OR = 0.87, 95% CI = 0.84 to 0.92, *P* = 2.43 × 10^−8^), particularly in the cross-ancestry analysis of the Asian and European populations (OR = 0.87, 95% CI = 0.83 to 0.91, *P* = 2.13 × 10^−9^). The further stratified analysis confirmed the association of rs3850997 with gastric cancer risk in both demographic (age and sex) and clinical (tumor site) subgroups without heterogeneity (fig. S4).

In silico analysis of rs3850997 and its corresponding host gene
---------------------------------------------------------------

The transcript biotype of ENST00000532936.1 harboring rs3850997 was defined as a processed transcript of the *RP11-166B2.1* gene, which was generally categorized as an ncRNA (also named as *lnc-RP11-166B2.1.1-2:1* in LNCipedia). The coding probability evaluation revealed an extremely low coding probability for ENST00000532936.1 \[probabilities of 0.0158 from Coding-Potential Assessment Tool (CPAT) and 0.0287 from iSeeRNA and a score of 9.7817 from PhyloCSF\]. The quantitative analysis showed that expression of ENST00000532936.1 was significantly lower in gastric cancer tissues than in normal tissues, based on evidences from both public and in-house datasets with five independent populations ([Fig. 2A](#F2){ref-type="fig"}). Similarly, this differential expression pattern was observed in gastric cell lines ([Fig. 2B](#F2){ref-type="fig"}). Moreover, this transcript includes 574 poly(A)-negative base pairs (bps) without a Kozak sequence and is enriched in the cytoplasm, as detected by both quantitative and fluorescence analyses ([Fig. 2C](#F2){ref-type="fig"} and fig. S5). On the basis of these results, the ENST00000532936.1 transcript is a novel long ncRNA (lncRNA) that is strongly correlated with gastric cancer and, hence, is named *Gastric Cancer Low-Expressed Transcript* (*GCLET*).

![The expression pattern of the lncRNA *GCLET* and genetic effect of rs3850997.\
(**A**) Both public and in-house datasets showed significantly down-regulated *GCLET* expression in gastric cancer tissues \[public databases: GSE13911, GSE37023, and GSE29272; in-house datasets: 51 pairs of tumor and normal tissues analyzed using reverse transcription polymerase chain reaction (PCR) and 20 pairs from one unpublished dataset detected using an SBC microarray\]. Red dots, tumor (T) tissues; blue dots, normal (N) tissues. (**B**) The constitutive expression of *GCLET* in gastric cancer cells (BGC-823, SGC-7901, and MGC-803) is significantly lower than that in normal gastric cell (GES-1). (**C**) The fractionation of gastric cell lysates reveals the cytoplasmic expression of *GCLET*. The *U6* RNA served as a positive control for nuclear gene expression. *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase. (**D**) An eQTL analysis for the association of rs3850997 and *GCLET* expression was conducted using 51 tumor tissues from Nanjing-1 and 280 tumor tissues from Nantong. *P* values were calculated using an unpaired *t* test, paired *t* test, Wilcoxon signed-rank test, and linear regression analysis. (**E**) The mediation model for the genetic effect of rs3850997 (exposure variable) on the risk of gastric cancer (dependent variable) through *GCLET* expression (mediator variable). The arrows indicate the direction of the mediation model.](aay5525-F2){#F2}

In addition, rs3850997 is located in the third intron of the *GCLET* gene. By analyzing the chromatin immunoprecipitation sequencing data deposited in Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenomics projects, the intronic region surrounding rs3850997 was subjected to deoxyribonuclease hypersensitivity and was enriched for multiple histone modifications and key transcription factor (TF) binding sites. Among the candidate TFs, CCCTC-binding factor (CTCF) presented the strongest binding affinity with the top 1000 scores (fig. S6A). Furthermore, specific to CTCF, we found that multiple CTCF binding sites were predicted in the region harboring rs3850997 using Find Individual Motif Occurrences (FIMO) ([@R19]) and CTCF-binding site database (CTCFBSDB) ([@R20]) and rs3850997 did not generate a new CTCF binding motif but affected the log-likelihood ratio for the match of CTCF to the T allele (*P*~T\ allele~ = 0.042) and G allele (*P*~G\ allele~ = 0.140; fig. S6B, bottom left). Besides, rs3850997 altered the DNA folding energy of the CTCF binding site (fig. S6C), indicating the easier access of CTCF to the region with T allele. These findings supported a prerequisite that rs3850997 might mediate the impact of CTCF on *GCLET* transcriptional activity.

Evaluation of the *GCLET*-mediated genetic effect of rs3850997 on gastric cancer risk
-------------------------------------------------------------------------------------

We then performed an eQTL analysis to evaluate the genetic effect of rs3850997 on *GCLET* expression. The protective rs3850997 G allele significantly increased *GCLET* expression in two independent sets (β~Nanjing-1~ = 0.004, *P*~trend~ = 0.043; β~Nantong~ = 0.011, *P*~trend~ = 0.004; [Fig. 2D](#F2){ref-type="fig"}). Because of the notable eQTL and risk effect of rs3850997, as well as the differential expression of *GCLET*, we hypothesized that *GCLET* served as a mediator of the effect of rs3850997 on gastric cancer risk. Using a causal mediation analysis, we observed a significant indirect effect of rs3850997 on gastric cancer susceptibility (OR~indirect~ = 0.987, 95% CI = 0.975 to 0.999, *P* = 0.018, 9.50% effects mediated; [Fig. 2E](#F2){ref-type="fig"}).

Allele-specific effect of rs3850997 on mediating *GCLET* expression
-------------------------------------------------------------------

We further exploited the allele-specific expression (ASE) analysis to dissect this cis-regulatory variability in gastric cancer susceptibility. As shown in [Fig. 3A](#F3){ref-type="fig"}, compared with the T risk allele, the G allele was selectively transcribed with a 2.3-fold increase in transcriptional activity (*P* = 0.003).

![Allele-specific effect of rs3850997.\
(**A**) *GCLET* expression displayed allele specificity, with a preference for the G allele of rs3850997. The ratio of signal density at rs3850997 was calculated using Sanger sequencing in both the genomic DNAs (gDNAs) and complementary DNAs (cDNAs) derived from 32 gastric cancer tissues carrying the TG genotype. *P* values were calculated using the Wilcoxon signed-rank test. siRNA, small interfering RNA. (**B**) In dual-luciferase reporter assays, a higher transcriptional activity of the *GCLET* promoter was observed with the rs3850997 G allele than with the T allele. (**C**) In electrophoretic mobility shift assays (EMSAs), the G allele of rs3850997 showed a lower binding affinity for the negative regulatory TF CTCF than the T allele. (**D**) ChIP and allele-specific quantitative polymerase chain reaction (qPCR) indicated that CTCF preferentially bound to the T allele at rs3850997. Notably, the PCR products shown in lanes 1 to 4 were amplified using primers specific for the human H19 imprinting control region, which served as positive controls (lane 1, 100- to 600-bp ladder; lane 2, CTCF binding product; lane 3, immunoglobulin G (IgG) binding product as a negative control; lane 4, input product), and the products shown in lanes 5 to 9 were amplified with primers specific for rs3850997 alleles (lane 5, 100- to 600-bp ladder; lanes 6 and 8, CTCF binding product for T and G alleles, respectively; lanes 7 and 9, IgG binding product for T and G alleles, respectively). (**E**) The left diagram showed the relative positions of the long-range regulation of rs3850997 on *GCLET* transcription. Target and Anchor were two primers for hybrid fragments; the blue blocks refer to exons in the *GCLET* gene; the colorful pies represent multiple TFs, and the red line indicates the *Pst1* restriction sites. TSS, transcription start site. The right plots showed the physical interactions of the rs3850997 intronic region with the *GCLET* promoter (top) as determined using PCR. The products from *Pst1*-digested cross-linked chromatin without ligation and noncross-linked gDNA with or without ligation were used as negative controls. We used the PCR products from gDNA that were not cleaved by any restriction enzyme as the loading controls (bottom).](aay5525-F3){#F3}

Next, we constructed in vitro and in vivo allele-specific assays to investigate the mechanism by which rs3850997 could regulate *GCLET* transcription. As shown in [Fig. 3B](#F3){ref-type="fig"}, compared with the *GCLET* promoter, the region containing the rs3850997 T allele notably repressed the transcriptional activity of the luciferase gene, while the G allele rescued this inhibitory effect on both constitutive (in red) and CTCF-overexpressing cells (in blue). The difference in luciferase activity between the T and G alleles of the region harboring rs3850997 was diminished by a *CTCF* small interfering RNA (in green), and both alleles could activate luciferase activity compared with the basal promoter.

We conducted an electrophoretic mobility shift assay (EMSA) with or without CTCF-containing nuclear extracts to independently verify the results described above. The supershift assays showed the preference of CTCF for the rs3850997 T allele probe ([Fig. 3C](#F3){ref-type="fig"}), but this effect was not observed in the total nucleoprotein assays (fig. S7A). Furthermore, we used chromatin immunoprecipitation (ChIP) assays with a CTCF-specific antibody to explore whether the binding of CTCF to the rs3850997-containing region occurred in MGC-803 cells (heterozygous for rs3850997; fig. S7B). Using ChIP followed by quantitative polymerase chain reaction (qPCR) with or without allele-specific primers, we confirmed that CTCF chromatin binding occurred at the rs3850997 risk-associated locus, and we preferentially precipitated the risk-associated T allele with CTCF ([Fig. 3D](#F3){ref-type="fig"}). Consistent with these findings, DNA sequencing of the ChIP products showed that unlike the input genomic DNA (gDNA), fragments precipitated with the anti-CTCF antibody were enriched for the T allele (fig. S7C). In addition, the region harboring rs3850997 was recognized as the modification region of active histones H3K4me1 and H3K27ac but had no allelic effect on histone modification (fig. S7D).

Furthermore, in silico analysis also predicted multiple CTCF binding sites in the promoter region of *GCLET* gene (fig. S6B, bottom right). Most of CTCF binding sites located in the region of rs3850997 and *GCLET* promoter were in the same motif direction aligning with the transcription, indicating a potential formation of a CTCF tandem loop. Subsequently, the chromosome conformation capture assay (3C) assay supported that the rs3850997 intronic region could physically juxtapose with the *GCLET* promoter and form an intron-promoter complex in the nucleus through a higher-order chromatin loop structure ([Fig. 3E](#F3){ref-type="fig"} and fig. S7E), which was in accordance with the finding from the in situ Hi-C data (fig. S6B, top) ([@R21]).

Association of *GCLET* expression and clinical characteristics
--------------------------------------------------------------

Apart from the risk SNP function, we investigated whether dysregulated *GCLET* expression correlated with gastric cancer progression. The survival analysis revealed a better survival for patients with higher *GCLET* expression than for those with lower levels \[*P*~log-rank~ = 0.005, hazard ratio (HR) = 0.70, 95% CI = 0.51 to 0.96; [Fig. 4A](#F4){ref-type="fig"} and fig. S8A\], but rs3850997 did not exert a significant effect on gastric cancer survival (*P*~log-rank~ = 0.670, HR = 0.85, 95% CI = 0.66 to 1.10; fig. S8A). Besides, the quantitative analysis revealed a substantial down-regulation of *GCLET* expression upon tumor progression to the advanced stage (especially the invasion depth and lymph node metastasis; [Fig. 4, B to D](#F4){ref-type="fig"}) but not tumor size, distant metastasis, and histological type (fig. S8, B to D).

![Association of *GCLET* expression with clinical features of gastric cancer and effect of *GCLET* on cellular phenotypes and molecular regulation.\
(**A**) Significant association of *GCLET* expression with the survival of gastric cancer, as determined using the log-rank test. (**B** to **D**) Significant associations of *GCLET* expression with clinical features, including tumor invasion (B), lymph node metastasis (C), and tumor-node-metastasis classification (D), as determined using a linear regression analysis. (**E** and **F**) Prominent effect of *GCLET* on gastric cancer cell proliferation, as assessed using the CCK8 assay (E) and colony-forming assay (F). OD, optical density. (**G**) Remarkable effects of *GCLET* on gastric cancer cell invasion and migration. (**H** and **I**) *GCLET* attenuated the effect of miR-27a-3p on the expression of its target gene *FOXP2*. Luciferase expression was reduced if the reporter plasmid contained the wild-type *FOXP2* 3′ untranslated region (3'UTR), and this effect was more notable when the reporter plasmids were cotransfected together with the miR-27a-3p mimics (H). *GCLET* independently increased the level of the FOXP2 protein and further rescued the inhibitory effect of miR-27a-3p on *FOXP2* expression (I).](aay5525-F4){#F4}

Effect of *GCLET* on cell and mouse phenotypes
----------------------------------------------

To address the clinical relevance of *GCLET*, we detected the biological impact of *GCLET* on cell and mouse models. As illustrated in [Fig. 4, E to G](#F4){ref-type="fig"}, *GCLET* overexpression significantly suppressed proliferation, clone formation, invasion, and migration of transiently transfected gastric cancer cells. Besides, the similar phenotypes were identified in stably transfected cells (fig. S9, A to C). Moreover, we injected MGC-803 cells carrying the *GCLET* or negative control (NC) lentiviral vector into nude mice. Consistent with the in vitro findings, *GCLET* overexpression significantly decreased the mean tumor weight and average tumor volume (fig. S9, D to G). The tumor tissues from mice inoculated with cells expressing *GCLET* showed increased expression of *GCLET* (fig. S9H) and significantly reduced expression of the proliferation marker Ki67 (fig. S9I).

Mechanistic significance of *GCLET* in gastric cancer etiology
--------------------------------------------------------------

According to the enrichment of *GCLET* in the cytoplasm, we investigated whether *GCLET* affected microRNA (miRNA)--mediated regulation of their shared targets in tumorigenesis. By combining two prediction algorithms from TargetScan and miRcode, we identified six miRNAs that matched the *GCLET* RNA sequences (fig. S10A) and identified only miR-27a-3p as a target of *GCLET* using luciferase reporter assays (fig. S10B).

We hypothesized that the lncRNA *GCLET* would compete for available miR-27a-3p and further regulate the expression of target genes shared by miR-27a-3p. Therefore, we conducted a systematic analysis to determine the targets of miR-27a-3p, which could also be regulated by *GCLET* (see Supplementary Materials and Methods). Among the 26 candidate targets (table S8), *FOXP2* exhibited the strongest correlation coefficient and was assessed as a putative shared target of both *GCLET* and miR-27a-3p in further investigations. Subsequently, the luciferase reporter assays revealed a significantly lower activity in cells expressing plasmids containing the *FOXP2* 3′ untranslated region (3'UTR) than that in cells expressing plasmids containing mutations; this effect was markedly promoted by the biological actions of miR-27a-3p ([Fig. 4H](#F4){ref-type="fig"}). Moreover, Western blot assays showed that miR-27a-3p markedly decreased the levels of the FOXP2 protein and *GCLET* rescued the suppressive effect of miR-27a-3p on the FOXP2 protein levels ([Fig. 4I](#F4){ref-type="fig"}). These results indicated the potential of *FOXP2* to serve as a miR-27a-3p target whose expression was regulated by *GCLET*.

Correlation with candidate genes expression
-------------------------------------------

We further explored the expression patterns of *CTCF*, *GCLET*, miR-27a-3p, and *FOXP2* and their correlations. The expressions of both *CTCF* and miR-27a-3p were greatly up-regulated in gastric cancer tissues, while both *GCLET* and *FOXP2* expressions were markedly down-regulated (fig. S10, C and D). Moreover, a notable expression correlation for each gene was observed in the cascade of *CTCF*, *GCLET*, miR-27a-3p, and *FOXP2* (fig. S10, C and D), except for the relationship of *GCLET* and miR-27a-3p (fig. S10E). In addition, after modifying the CTCF expression pattern in gastric cancer cells, we observed an inhibitory effect of CTCF on *GCLET* expression (fig. S11A).

Together, we identified a novel gastric cancer susceptibility locus in a previously unknown lncRNA *GCLET* at 16p13 ([Fig. 5](#F5){ref-type="fig"}). SNP rs3850997 T\>G in this region represents a potential causal variant that may drive the long-range regulation of *GCLET* expression through attenuating the binding affinity of CTCF, which, in turn, was associated with a decreased gastric cancer risk. Moreover, *GCLET* affected gastric cancer progression by competing with miR-27a-3p to regulate *FOXP2* expression in oncogenesis.

![Graphical representation of our findings.\
SNP rs3850997 was significantly associated with a decreased risk of gastric cancer, most likely by altering the CTCF binding affinity and mediating a long-range regulatory effect on the expression of the lncRNA *GCLET*. In addition, *GCLET* competed with miR-27a-3p to regulate *FOXP2* expression, tumor growth, invasion, and migration.](aay5525-F5){#F5}

DISCUSSION
==========

GWAS has uncovered thousands of genetic variants related to human complex traits and diseases, and approximately 90% of these loci are located in noncoding regions. Although the functional studies underlying the observed statistical associations with disease risk have lagged, emerging evidence has demonstrated the allele-specific regulatory effects of risk variants (even in noncoding) on the development and progression of traits, which provides additional insights into the causal genetic variants and biological mechanisms ([@R16], [@R22]). In this study, our integrated analysis of gastric cancer GWAS data revealed that the potential causal risk SNP rs3850997 altered a long-range allele-specific effect on the transcriptional activity of the novel lncRNA *GCLET* and was involved in gastric oncogenesis.

Initially, we observed a significant enrichment of genetic variants in the subgroup of the combination, along with its significant association with gastric cancer risk using gene-set analysis. This finding supported the extended meaning that the region enriched with a large portion of risk variants could exert the potential biological role in disease, particularly the combination in gastric cancer etiology in this study. Subsequently, we adopted a delicate gene-set analysis to fill the gap in the missing heritability of conventional analyses ([@R23]). After two-step gene-set analysis and independent validations, we identified that rs3850997 T\>G was significantly associated with a decreased risk of gastric cancer, without demographic and clinical specificity. This association was further confirmed through a cross-ancestry analysis. In the original gastric cancer GWAS by single-locus analysis, rs2274223 was one of the most significant signals associated with gastric cancer risk (*P* = 8.40 × 10^−9^) ([@R6]). Thus, we enrolled both rs2274223 and rs3850997 in the logistic regression model to confirm the independent genetic effect of rs3850997 on gastric cancer risk. All these findings support the hypothesis that rs3850997 represents a potential causal variant for gastric cancer risk.

Currently, the integration of omics data has advanced our knowledge of the role of genomics and epigenomics in cancer etiology and pathology as a bridge between an association and causality. Using both functional annotations and experimental studies, the intronic region of the lncRNA *GCLET* surrounding rs3850997 displayed significantly selective transcription, which helped rs3850997 exert an ASE effect on the expression of its assigned gene *GCLET*. In addition, this phenomenon partially mediated the genetic effect of rs3850997 on gastric cancer risk.

Progressive studies have revealed that noncoding risk variants function as cis-/trans-regulatory elements involved in key biological processes, including DNA methylation, TF binding affinity, and histone modification ([@R17], [@R22]). We primarily treated CTCF as a candidate regulatory element that disrupted the allele-specific effect of rs3850997 on *GCLET* expression. CTCF, a well-known TF involved in genomic and epigenomic regulation, facilitates changes in cell phenotypes that participate in the development and progression of cancers ([@R24]). The subsequent in vitro and in vivo studies revealed that the protection-associated rs3850997 G allele escaped its surrounding regulatory element by binding to the inhibitor CTCF and further exerted long-range regulatory effects on *GCLET* transcription by forming an intron-promoter loop structure. Collectively, rs3850997 plausibly drives the long-range regulation of *GCLET* expression, explaining its risk effect on gastric cancer etiology. Moreover, any state-of-the-art technologies, such as the CRISPR-Cas9--mediated genome editing approach, will be further used to demonstrate and define the real genes affected by the risk T allele.

LncRNAs are aberrantly expressed in a broad spectrum of cancers with disease- and stage-restricted expression and represent potentially important diagnostic biomarkers and therapeutic targets in cancer development and progression ([@R25], [@R26]). In the present study, higher expression of *GCLET* was markedly correlated with less progression and improved survival of patients with gastric cancer by diminishing malignant tumor phenotypes. Thus, *GCLET* represents a potential biomarker for the evaluation of gastric cancer outcome. Besides, regarding the mechanism, RNA transcripts, especially cytoplasm-enriched lncRNAs, are well established as competing endogenous RNAs that sponge miRNAs involved in human development and diseases ([@R27], [@R28]). Notably, miR-27a-3p is an oncogene that is involved in gastric cancer growth and drug resistance and potentially serves as a gastric cancer outcome biomarker ([@R29], [@R30]). We demonstrated that *GCLET* did not affect the abundance of miR-27a-3p but antagonized the negative modulatory effect of miR-27a-3p on its target *FOXP2*, contributing to the development and progression of gastric cancer. These findings need to be confirmed in further comprehensive functional studies. In addition, a future study will be conducted to comprehensively evaluate the predictive value of a set of biomarkers combining the expression of *CTCF*, *GCLET*, miR-27a-3p, and *FOXP2* and the genotypes of rs3850997 for gastric cancer patient survival, progression, and therapeutic effects.

In summary, our findings suggest that 16p13 is a novel gastric cancer susceptibility locus where a potential causal variant rs3850997 T\>G drives the long-range regulation of the expression of the first-reported lncRNA *GCLET* through altering the CTCF binding affinity. Besides, *GCLET* is involved in tumorigenesis by competing with miR-27a-3p to increase *FOXP2* expression ([Fig. 5](#F5){ref-type="fig"}). This study not only provides important insight into the role of "post-GWAS" in determining genetic susceptibility to cancer but also establishes the basis for the identification of genetic and epigenetic biomarkers for further screening and prognostic programs.

MATERIALS AND METHODS
=====================

Global overview of genetic variants based on transcript distribution
--------------------------------------------------------------------

Biotype annotation was supported by the GENCODE project (v19), which comprised a total of 229,917 transcripts from 85,305 genes, including 81,184 transcripts for protein-coding genes and 148,103 for ncRNA genes. The details for each biotype are listed in fig. S1A and table S1.

Study subjects
--------------

The whole-genome genotyping data of 1625 gastric cancer cases and 2100 controls from northwestern China were used for the GWAS stage ([@R6]). In the validation study, we enrolled 5353 cases and 6685 controls from six independent sets. All cases were diagnosed and histopathologically confirmed as gastric cancer at the hospitals, and the controls were genetically unrelated to the cases within the surrounding region. All enrollment criteria have been previously described in detail ([@R6], [@R14]). The demographic characteristics of all individuals are shown in table S9. The study was approved by the ethical committees of all institutions.

Imputation in the GWAS database
-------------------------------

For the gastric cancer GWAS, the nongenotyped variants were imputed on the basis of the 1000 Genomes Project (phase 1 integrated release 3, March 2012) using IMPUTE ([@R31]). The imputed SNPs were then excluded on the basis of the criteria of a minor allele frequency of \<0.01, a genotype call rate of \<95%, and *P* \< 0.001 for Hardy-Weinberg equilibrium (HWE). A total of 4,817,140 variants were included in the analysis of the association with gastric cancer using a probabilistic dosage model in SNPTEST v2.5 ([@R32]).

Functional prediction for SNPs and assigned genes
-------------------------------------------------

The functional scores for candidate SNPs were calculated using an aggregation of RegulomeDB and HaploReg v4; each provided the regulatory scores for candidate SNPs, including the items of protein binding, chromatin changing, and eQTL (table S5). The genomic sequences of multiple species were obtained from the UCSC Genome Browser to conduct the conservation assessment. Haplotter displayed the results of a scan for positive selection in the human genome and detected recent positive selection with iHSs ([@R33]). The Genotype-Tissue Expression project is a comprehensive public resource that was used to study tissue-specific eQTL. FIMO ([@R19]) and CTCFBSDB ([@R20]) were applied to predict the change in CTCF motif and binding sites affected by the risk variant. The mfold tool ([@R34]) calculated the energy change in DNA folding affected by the risk variant. The mature sequences of the *GCLET* transcript were derived from the Ensembl genome and LNCipedia v5.0 databases ([@R35]). Three stringent methods, CPAT ([@R36]), iSeeRNA ([@R37]), and PhyloCSF ([@R38]), were used to evaluate the coding probability of candidate lncRNAs.

Publicly available clinical datasets
------------------------------------

We obtained three independent gastric cancer datasets from Gene Expression Omnibus to detect *GCLET* expression pattern, including GSE13911 (38 gastric tumor and 31 normal tissues) ([@R39]), GSE37023 (29 tumors and 36 normal tissues) ([@R40]), and GSE29272 (62 pairs of tumor and adjacent normal tissues) ([@R41]). Another dataset with 274 gastric cancer tissues and 33 normal tissues from The Cancer Genome Atlas allowed us to analyze the correlations between miR-27a-3p and its candidate targets by calculating log~2~(*X* + 1) transformed values.

Analysis of ASE in tissues
--------------------------

ASE was detected using Sanger sequencing with specific primers (table S10). We examined the sequences of the region surrounding rs3850997 in 32 gastric cancer tissues from heterozygous carriers (T/G) using TaqMan assays, with products of approximately 400 bps. ASE ratio (G versus T) was calculated by normalizing the ratio between the peak areas of the two alleles (T/G) in complementary DNA (cDNA) samples with the same parameters in gDNA (1)$$E\left( \frac{G}{T} \right) = \frac{1}{n}\sum_{i = 1}^{n}\left( \frac{K_{\text{cDNA}}\left( \frac{G}{T} \right)}{K_{\text{gDNA}}\left( \frac{G}{T} \right)} \right)_{i}$$

In [Eq. 1](#E1){ref-type="disp-formula"}, *K* represents the mean peak ratio of the peak area G allele/peak area T allele, and *E* represents the mean adjusted peak ratio of the *K*~cDNA~/*K*~gDNA~.

ChIP assay
----------

ChIP experiments were strictly performed according to the manufacturer's instructions (53009, Active Motif) using antibodies against CTCF (2418, Cell Signaling Technology), H3K4me1 (ab8895, Abcam), K3K27ac (ab4729, Abcam), and normal rabbit immunoglobulin G (2729, Cell Signaling Technology). Briefly, cells cultured in 15-cm plates were cross-linked with fixation solution (1% formaldehyde) at room temperature for 10 min. The reaction was quenched with Glycine Stop-Fix Solution. Cells were washed twice with cold phosphate-buffered saline (PBS), collected with cell scraping solution \[1× PBS with 100 mM phenylmethylsulfonyl fluoride (PMSF)\], and centrifuged into a pellet. The pellet was resuspended in cold lysis buffer supplemented with protease inhibitor cocktail (PIC) and PMSF to isolate nuclei. The centrifuged nuclear fraction was resuspended in digestion buffer; then, a working stock of enzymatic shearing cocktail was added and incubated for 15 min (the optimal enzymatic shearing condition) at 37°C. The shearing of the chromatin samples was terminated with 0.5 M EDTA, and the samples were collected by centrifugation. Chromatin lysates were then diluted with ChIP buffer 1 supplemented with Protein G magnetic beads and PIC and subjected to immunoprecipitation with candidate antibodies overnight. Subsequently, the complexes were washed with ChIP buffer 1 and ChIP buffer 2 on a magnetic stand, eluted with Elution Buffer AM2, and incubated for 15 min at room temperature. Reverse cross-linking buffer was added to the eluted chromatin, which was then incubated for 2.5 hours at 65°C, followed by a 1-hour incubation with Proteinase K at 37°C. After the addition of Proteinase K stop solution, DNA was purified from the collected liquid with a QIAquick PCR Purification kit (QIAGEN) and analyzed using qPCR with specific primers for CTCF binding sites and histones modification sites (table S10). The primers specific for the prostate-specific antigen enhancer ([@R42]) and HOXC-AS3 ([@R43]) served as positive controls for active histones modification.

ASE analysis in ChIP reaction
-----------------------------

For allele-specific quantitative reverse transcription PCR, the DNA products of ChIP were quantitated using the allele-specific qPCR method, which is similar to normal qPCR with the allele-specific amplification of the rs3850997 region containing the T or G allele. The primers designed to specifically amplify the rs3850997 region with the T or G allele were listed in table S10. In addition, the difference in peak areas between the T and G alleles from the ChIP DNA products was detected using Sanger sequencing with the same primers used for ChIP experiments.

Chromosome conformation capture assay
-------------------------------------

Briefly, cross-linking was achieved by incubating 1 million cells with 2% formaldehyde for fixation and stopped by the addition of glycine. Cells were then lysed in lysis buffer supplemented with protease inhibitors for 60 min at 4°C. The nuclei were suspended in 1.2× restriction buffer and incubated for 1 hour at 37°C. Next, Triton X-100 was added and incubated for 1 hour at 37°C. The restriction enzyme *Pst1* was chosen to cleave the DNA because the recognition sequence CTGCAG was identified in both the rs3850997 intronic region and the *GCLET* promoter. One hundred units of *Pst1* was added, and the samples were subjected to a 22-hour digestion. The reaction was stopped by the addition of SDS and a 20-min incubation at 65°C. Approximately 2 μg of digested chromatin was diluted in 800 μl of ligation buffer. When the reaction was cooled to 16°C, 2000 U of T4 DNA ligase was added and incubated overnight. Then, the chromatin mixtures were incubated with Proteinase K (100 μg/ml) at 65°C overnight to reverse the cross-links. RNA was digested with ribonuclease A at 37°C for 30 min. The captured sample was purified with a QIAquick PCR purification kit (QIAGEN). The DNA extract was then amplified with PCR using the specific primers listed in table S10, and the primers were designed around the *Pst1* recognition site. PCR products from *Pst1*-digested cross-linked chromatin without ligation and non--cross-linked gDNA with or without ligation were used as negative controls. All PCR products were sequenced.

Statistical analysis
--------------------

The hypergeometric test deposited in *dhyper* function of R stats package was used to assess the enrichment significance for four classifications of gene types. The two-stage gene-set analysis was conducted using a sequence kernel association test, which was implemented in the sequence kernel association optimal test ([@R23]). A logistic regression analysis was performed to determine the association of rs3850997 and gastric cancer risk after adjustment for available covariates in each study. The inverse variance method for meta-analysis was performed to merge the effects of rs3850997 reported in all available studies.

Potential causal variants were identified using the credible set analysis with Bayesian fine-mapping algorithm FM-summary ([@R18], [@R44]). We split the analyses into four main scenarios in the following predefined order to evaluate the association between candidate variant and gastric cancer risk underlying the causal mediation pathway through gene expression: (i) merging all associations between genetic variant and gastric cancer risk; (ii) merging all associations between genetic variant and gene expression; (iii) merging all associations between gene expression and gastric cancer risk; and (iv) causal inference analysis. The indirect effect of genetic variant on gastric cancer risk through gene expression was estimated using [Eq. 2](#E2){ref-type="disp-formula"}, as well as the proportion of the effect mediated (EM%)$$\text{OR}_{\text{indirect}} = e^{\beta_{(b)}*\beta_{(c)}}$$$$\text{EM}\% = \frac{\beta_{(b)}*\beta_{(c)}}{\beta(a)}$$

The statistical *P* value for OR~indirect~ was determined using the Sobel test.

A linear regression analysis was used to detect the eQTL effect and the relationship between rs3850997 and clinical phenotypes. We performed both Kaplan-Meier survival analysis and Cox multivariate regression model to calculate log-rank *P* value and HR for the association between *GCLET* expression or rs3850997 genotypes and 5-year survival of patients with gastric cancer. The adjustment was from the demographic characteristics (age and sex) and clinical features (tumor size, tumor-node-metastasis, and histological type). Paired or unpaired *t* tests, rank-sum test, and Pearson's χ^2^ test were performed for continuous or categorical variables, as appropriate. PLINK 1.90 and R 3.4.2 were used for general statistical analyses.
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